BioSpace News Archive

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs.

Partnership expands the distributed manufacturing of ARTBIO’s novel Pb212-based alpha radioligand therapy for the treatment of prostate cancer

Injecting neuroblastoma tumors with Zika virus shrank or eliminated those tumors in studies with mice, suggesting that the virus could someday serve as an effective cancer therapy, according to a study led by Nemours Children’s Health researchers and published in Cancer Research Communications, a journal of the American Association for Cancer Research.

Nura Pain Clinics, the Twin Cities’ foremost multidisciplinary pain management clinic, announced today that the first patient in Minnesota has been implanted with the new Medtronic SynchroMed™ III implantable drug pump for the treatment of chronic pain.

Mitochon Pharmaceuticals today announced that it was awarded approval from EMA to begin enrollment for a Phase I/IIa biomarker study in Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Huntington’s Disease (HD) and Alzheimer’s Disease (AD) participants.

Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing drugs targeting the endocannabinoid system, has received clearance of its Investigational New Drug

Extreme weather conditions and power outages are especially common in the winter season. Continue reading to learn more about how to keep your food safe during an emergency.

AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming Specialty and Rare Disease drug launches and cell and gene therapies, biosimilars and generics.

Critical Path Institute announced that Klaus Romero, M.D., M.S., FCP, has been named its new Chief Executive Officer.